APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-oncology Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Immuno-oncology Drugs Industry Growth and Trends Forecast to 2032

22 December 2025123 pages

Choose your research edition.

Industry ResearchImmuno-oncology Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-oncology Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Immuno-oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-oncology Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-oncology Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

According to APO Research, the global Immuno-oncology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Immuno-oncology Drugs market include Sanofi S.A., Johnson & Johnson, Merck & Co., Lonza Group, Eli Lilly and Company, Pfizer Inc., Ferring Pharmaceuticals, Amgen, Inc and AbbVie, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Immuno-oncology Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Immuno-oncology Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Immuno-oncology Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Immuno-oncology Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Immuno-oncology Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Immuno-oncology Drugs Market by Company

Sanofi S.A.

Johnson & Johnson

Merck & Co.

Lonza Group

Eli Lilly and Company

Pfizer Inc.

Ferring Pharmaceuticals

Amgen, Inc

AbbVie, Inc.

AstraZeneca, Plc

Spring Bank Pharmaceuticals, Inc.

Prometheus Therapeutics & Diagnostics

Novartis International AG

Incyte

ImmunoCellular Therapeutics

Hoffmann-La Roche AG

Gilead Sciences Inc.

Galena Biopharma

Enzo Biochem, Inc.

EMD Serono, Inc.

Dendreon Corporation

Celldex Therapeutics

Celgene Corporation

Bristol-Myers Squibb

Bio-Rad Laboratories, Inc.

Bavarian Nordic

Avantor, Inc.

Agilent Technologies Inc.

Agenus Inc.

Aduro BioTech

Immuno-oncology Drugs Segment by Type

Oncolytic Virus

Immune System Modulators

Immune Checkpoint Inhibitors

Cancer Vaccines

Others

Immuno-oncology Drugs Segment by Application

Clinics

Hospitals

Community Centers

Immuno-oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Immuno-oncology Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Immuno-oncology Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Immuno-oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Immuno-oncology Drugs Market Share by Region (2021-2026) Table 4. Global Immuno-oncology Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Immuno-oncology Drugs Market Share by Region (2027-2032) Table 6. Global Immuno-oncology Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Immuno-oncology Drugs Market Size Share by Type (2021-2026) Table 9. Global Immuno-oncology Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Immuno-oncology Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Immuno-oncology Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Immuno-oncology Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Immuno-oncology Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Immuno-oncology Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Immuno-oncology Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Immuno-oncology Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Immuno-oncology Drugs Market Size Share by Application (2021-2026) Table 24. Global Immuno-oncology Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Immuno-oncology Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Immuno-oncology Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Immuno-oncology Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Immuno-oncology Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Immuno-oncology Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Immuno-oncology Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Immuno-oncology Drugs Industry Trends Table 37. Immuno-oncology Drugs Industry Drivers Table 38. Immuno-oncology Drugs Industry Opportunities and Challenges Table 39. Immuno-oncology Drugs Industry Restraints Table 40. Global Immuno-oncology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Immuno-oncology Drugs Revenue Market Share by Company (2021-2026) Table 42. Global Immuno-oncology Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Immuno-oncology Drugs Key Company Headquarters & Area Served Table 44. Global Immuno-oncology Drugs Company, Product Type & Application Table 45. Global Immuno-oncology Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sanofi S.A. Company Information Table 49. Sanofi S.A. Business Overview Table 50. Sanofi S.A. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sanofi S.A. Immuno-oncology Drugs Product Portfolio Table 52. Sanofi S.A. Recent Development Table 53. Johnson & Johnson Company Information Table 54. Johnson & Johnson Business Overview Table 55. Johnson & Johnson Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Johnson & Johnson Immuno-oncology Drugs Product Portfolio Table 57. Johnson & Johnson Recent Development Table 58. Merck & Co. Company Information Table 59. Merck & Co. Business Overview Table 60. Merck & Co. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Merck & Co. Immuno-oncology Drugs Product Portfolio Table 62. Merck & Co. Recent Development Table 63. Lonza Group Company Information Table 64. Lonza Group Business Overview Table 65. Lonza Group Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Lonza Group Immuno-oncology Drugs Product Portfolio Table 67. Lonza Group Recent Development Table 68. Eli Lilly and Company Company Information Table 69. Eli Lilly and Company Business Overview Table 70. Eli Lilly and Company Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Eli Lilly and Company Immuno-oncology Drugs Product Portfolio Table 72. Eli Lilly and Company Recent Development Table 73. Pfizer Inc. Company Information Table 74. Pfizer Inc. Business Overview Table 75. Pfizer Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Pfizer Inc. Immuno-oncology Drugs Product Portfolio Table 77. Pfizer Inc. Recent Development Table 78. Ferring Pharmaceuticals Company Information Table 79. Ferring Pharmaceuticals Business Overview Table 80. Ferring Pharmaceuticals Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio Table 82. Ferring Pharmaceuticals Recent Development Table 83. Amgen, Inc Company Information Table 84. Amgen, Inc Business Overview Table 85. Amgen, Inc Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Amgen, Inc Immuno-oncology Drugs Product Portfolio Table 87. Amgen, Inc Recent Development Table 88. AbbVie, Inc. Company Information Table 89. AbbVie, Inc. Business Overview Table 90. AbbVie, Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. AbbVie, Inc. Immuno-oncology Drugs Product Portfolio Table 92. AbbVie, Inc. Recent Development Table 93. AstraZeneca, Plc Company Information Table 94. AstraZeneca, Plc Business Overview Table 95. AstraZeneca, Plc Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio Table 97. AstraZeneca, Plc Recent Development Table 98. Spring Bank Pharmaceuticals, Inc. Company Information Table 99. Spring Bank Pharmaceuticals, Inc. Business Overview Table 100. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio Table 102. Spring Bank Pharmaceuticals, Inc. Recent Development Table 103. Prometheus Therapeutics & Diagnostics Company Information Table 104. Prometheus Therapeutics & Diagnostics Business Overview Table 105. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio Table 107. Prometheus Therapeutics & Diagnostics Recent Development Table 108. Novartis International AG Company Information Table 109. Novartis International AG Business Overview Table 110. Novartis International AG Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Novartis International AG Immuno-oncology Drugs Product Portfolio Table 112. Novartis International AG Recent Development Table 113. Incyte Company Information Table 114. Incyte Business Overview Table 115. Incyte Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Incyte Immuno-oncology Drugs Product Portfolio Table 117. Incyte Recent Development Table 118. ImmunoCellular Therapeutics Company Information Table 119. ImmunoCellular Therapeutics Business Overview Table 120. ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio Table 122. ImmunoCellular Therapeutics Recent Development Table 123. Hoffmann-La Roche AG Company Information Table 124. Hoffmann-La Roche AG Business Overview Table 125. Hoffmann-La Roche AG Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio Table 127. Hoffmann-La Roche AG Recent Development Table 128. Gilead Sciences Inc. Company Information Table 129. Gilead Sciences Inc. Business Overview Table 130. Gilead Sciences Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio Table 132. Gilead Sciences Inc. Recent Development Table 133. Galena Biopharma Company Information Table 134. Galena Biopharma Business Overview Table 135. Galena Biopharma Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Galena Biopharma Immuno-oncology Drugs Product Portfolio Table 137. Galena Biopharma Recent Development Table 138. Enzo Biochem, Inc. Company Information Table 139. Enzo Biochem, Inc. Business Overview Table 140. Enzo Biochem, Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio Table 142. Enzo Biochem, Inc. Recent Development Table 143. EMD Serono, Inc. Company Information Table 144. EMD Serono, Inc. Business Overview Table 145. EMD Serono, Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio Table 147. EMD Serono, Inc. Recent Development Table 148. Dendreon Corporation Company Information Table 149. Dendreon Corporation Business Overview Table 150. Dendreon Corporation Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 151. Dendreon Corporation Immuno-oncology Drugs Product Portfolio Table 152. Dendreon Corporation Recent Development Table 153. Celldex Therapeutics Company Information Table 154. Celldex Therapeutics Business Overview Table 155. Celldex Therapeutics Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 156. Celldex Therapeutics Immuno-oncology Drugs Product Portfolio Table 157. Celldex Therapeutics Recent Development Table 158. Celgene Corporation Company Information Table 159. Celgene Corporation Business Overview Table 160. Celgene Corporation Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 161. Celgene Corporation Immuno-oncology Drugs Product Portfolio Table 162. Celgene Corporation Recent Development Table 163. Bristol-Myers Squibb Company Information Table 164. Bristol-Myers Squibb Business Overview Table 165. Bristol-Myers Squibb Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 166. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio Table 167. Bristol-Myers Squibb Recent Development Table 168. Bio-Rad Laboratories, Inc. Company Information Table 169. Bio-Rad Laboratories, Inc. Business Overview Table 170. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 171. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio Table 172. Bio-Rad Laboratories, Inc. Recent Development Table 173. Bavarian Nordic Company Information Table 174. Bavarian Nordic Business Overview Table 175. Bavarian Nordic Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 176. Bavarian Nordic Immuno-oncology Drugs Product Portfolio Table 177. Bavarian Nordic Recent Development Table 178. Avantor, Inc. Company Information Table 179. Avantor, Inc. Business Overview Table 180. Avantor, Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 181. Avantor, Inc. Immuno-oncology Drugs Product Portfolio Table 182. Avantor, Inc. Recent Development Table 183. Agilent Technologies Inc. Company Information Table 184. Agilent Technologies Inc. Business Overview Table 185. Agilent Technologies Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 186. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio Table 187. Agilent Technologies Inc. Recent Development Table 188. Agenus Inc. Company Information Table 189. Agenus Inc. Business Overview Table 190. Agenus Inc. Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 191. Agenus Inc. Immuno-oncology Drugs Product Portfolio Table 192. Agenus Inc. Recent Development Table 193. Aduro BioTech Company Information Table 194. Aduro BioTech Business Overview Table 195. Aduro BioTech Immuno-oncology Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 196. Aduro BioTech Immuno-oncology Drugs Product Portfolio Table 197. Aduro BioTech Recent Development Table 198. North America Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 199. North America Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 200. North America Immuno-oncology Drugs Market Share by Country (2021-2026) Table 201. North America Immuno-oncology Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 202. North America Immuno-oncology Drugs Market Share Forecast by Country (2027-2032) Table 203. Europe Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 204. Europe Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 205. Europe Immuno-oncology Drugs Market Share by Country (2021-2026) Table 206. Europe Immuno-oncology Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 207. Europe Immuno-oncology Drugs Market Share Forecast by Country (2027-2032) Table 208. Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 209. Asia-Pacific Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 210. Asia-Pacific Immuno-oncology Drugs Market Share by Country (2021-2026) Table 211. Asia-Pacific Immuno-oncology Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 212. Asia-Pacific Immuno-oncology Drugs Market Share Forecast by Country (2027-2032) Table 213. Latin America Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 214. Latin America Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 215. Latin America Immuno-oncology Drugs Market Share by Country (2021-2026) Table 216. Latin America Immuno-oncology Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 217. Latin America Immuno-oncology Drugs Market Share Forecast by Country (2027-2032) Table 218. Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 219. Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021-2026) & (US$ Million) Table 220. Middle East & Africa Immuno-oncology Drugs Market Share by Country (2021-2026) Table 221. Middle East & Africa Immuno-oncology Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 222. Middle East & Africa Immuno-oncology Drugs Market Share Forecast by Country (2027-2032) Table 223. Research Programs/Design for This Report Table 224. Authors List of This Report Table 225. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Immuno-oncology Drugs Product Image Figure 3. Global Immuno-oncology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global Immuno-oncology Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global Immuno-oncology Drugs Market Share by Region (2021-2032) Figure 7. North America Immuno-oncology Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Immuno-oncology Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Immuno-oncology Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Oncolytic Virus Image Figure 13. Global Oncolytic Virus Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Immune System Modulators Image Figure 15. Global Immune System Modulators Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Immune Checkpoint Inhibitors Image Figure 17. Global Immune Checkpoint Inhibitors Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Cancer Vaccines Image Figure 19. Global Cancer Vaccines Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Others Image Figure 21. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Immuno-oncology Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Immuno-oncology Drugs Market Share by Type 2025 VS 2032 Figure 24. North America Immuno-oncology Drugs Market Size Share by Type (2021-2032) Figure 25. Europe Immuno-oncology Drugs Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Immuno-oncology Drugs Market Size Share by Type (2021-2032) Figure 27. Latin America Immuno-oncology Drugs Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Immuno-oncology Drugs Market Size Share by Type (2021-2032) Figure 29. Clinics Image Figure 30. Global Clinics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Hospitals Image Figure 32. Global Hospitals Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Community Centers Image Figure 34. Global Community Centers Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Global Immuno-oncology Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Immuno-oncology Drugs Market Share by Application 2025 VS 2032 Figure 37. North America Immuno-oncology Drugs Market Size Share by Application (2021-2032) Figure 38. Europe Immuno-oncology Drugs Market Size Share by Application (2021-2032) Figure 39. Asia-Pacific Immuno-oncology Drugs Market Size Share by Application (2021-2032) Figure 40. Latin America Immuno-oncology Drugs Market Size Share by Application (2021-2032) Figure 41. Middle East and Africa Immuno-oncology Drugs Market Size Share by Application (2021-2032) Figure 42. Global Top 5 and 10 Immuno-oncology Drugs Players Market Share by Revenue in 2025 Figure 43. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 44. North America Immuno-oncology Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. North America Immuno-oncology Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. North America Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 47. Europe Immuno-oncology Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Immuno-oncology Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 50. Asia-Pacific Immuno-oncology Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Asia-Pacific Immuno-oncology Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Asia-Pacific Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 53. Latin America Immuno-oncology Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Immuno-oncology Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 56. Middle East & Africa Immuno-oncology Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Middle East & Africa Immuno-oncology Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 58. Middle East & Africa Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 59. Years Considered Figure 60. Research Process Figure 61. Key Executives Interviewed

Scope & coverage.

Types
  • Oncolytic Virus
  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Others
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co.
  • Lonza Group
  • Eli Lilly and Company
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Amgen, Inc
  • AbbVie, Inc.
  • AstraZeneca, Plc
  • Spring Bank Pharmaceuticals, Inc.
  • Prometheus Therapeutics & Diagnostics
  • Novartis International AG
  • Incyte
  • ImmunoCellular Therapeutics
  • Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • Galena Biopharma
  • Enzo Biochem, Inc.
  • EMD Serono, Inc.
  • Dendreon Corporation
  • Celldex Therapeutics
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Bavarian Nordic
  • Avantor, Inc.
  • Agilent Technologies Inc.
  • Agenus Inc.
  • Aduro BioTech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Immuno-oncology Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Immuno-oncology Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global Immuno-oncology Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global Immuno-oncology Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions Immuno-oncology Drugs Market Size (2021-2032)
  8. 1.5.1 North America Immuno-oncology Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Immuno-oncology Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Immuno-oncology Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate (2021-2032)
2 Immuno-oncology Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Oncolytic Virus
  3. 2.1.2 Immune System Modulators
  4. 2.1.3 Immune Checkpoint Inhibitors
  5. 2.1.4 Cancer Vaccines
  6. 2.1.5 Others
  7. 2.2 Global Immuno-oncology Drugs Market Size by Type
  8. 2.2.1 Global Immuno-oncology Drugs Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Immuno-oncology Drugs Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Immuno-oncology Drugs Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Immuno-oncology Drugs Market Size by Regions
  12. 2.3.1 North America Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Immuno-oncology Drugs Market Size Breakdown by Type (2021-2026)
3 Immuno-oncology Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Clinics
  3. 3.1.2 Hospitals
  4. 3.1.3 Community Centers
  5. 3.2 Global Immuno-oncology Drugs Market Size by Application
  6. 3.2.1 Global Immuno-oncology Drugs Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Immuno-oncology Drugs Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Immuno-oncology Drugs Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Immuno-oncology Drugs Market Size by Regions
  10. 3.3.1 North America Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Immuno-oncology Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Immuno-oncology Drugs Industry Trends
  2. 4.2 Immuno-oncology Drugs Industry Drivers
  3. 4.3 Immuno-oncology Drugs Industry Opportunities and Challenges
  4. 4.4 Immuno-oncology Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Immuno-oncology Drugs Revenue (2021-2026)
  2. 5.2 Global Immuno-oncology Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Immuno-oncology Drugs Key Company Headquarters & Area Served
  4. 5.4 Global Immuno-oncology Drugs Company, Product Type & Application
  5. 5.5 Global Immuno-oncology Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Immuno-oncology Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Immuno-oncology Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Immuno-oncology Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sanofi S.A.
  2. 6.1.1 Sanofi S.A. Company Information
  3. 6.1.2 Sanofi S.A. Business Overview
  4. 6.1.3 Sanofi S.A. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sanofi S.A. Immuno-oncology Drugs Product Portfolio
  6. 6.1.5 Sanofi S.A. Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Merck & Co.
  14. 6.3.1 Merck & Co. Company Information
  15. 6.3.2 Merck & Co. Business Overview
  16. 6.3.3 Merck & Co. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Merck & Co. Immuno-oncology Drugs Product Portfolio
  18. 6.3.5 Merck & Co. Recent Developments
  19. 6.4 Lonza Group
  20. 6.4.1 Lonza Group Company Information
  21. 6.4.2 Lonza Group Business Overview
  22. 6.4.3 Lonza Group Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Lonza Group Immuno-oncology Drugs Product Portfolio
  24. 6.4.5 Lonza Group Recent Developments
  25. 6.5 Eli Lilly and Company
  26. 6.5.1 Eli Lilly and Company Company Information
  27. 6.5.2 Eli Lilly and Company Business Overview
  28. 6.5.3 Eli Lilly and Company Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio
  30. 6.5.5 Eli Lilly and Company Recent Developments
  31. 6.6 Pfizer Inc.
  32. 6.6.1 Pfizer Inc. Company Information
  33. 6.6.2 Pfizer Inc. Business Overview
  34. 6.6.3 Pfizer Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Inc. Immuno-oncology Drugs Product Portfolio
  36. 6.6.5 Pfizer Inc. Recent Developments
  37. 6.7 Ferring Pharmaceuticals
  38. 6.7.1 Ferring Pharmaceuticals Company Information
  39. 6.7.2 Ferring Pharmaceuticals Business Overview
  40. 6.7.3 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio
  42. 6.7.5 Ferring Pharmaceuticals Recent Developments
  43. 6.8 Amgen, Inc
  44. 6.8.1 Amgen, Inc Company Information
  45. 6.8.2 Amgen, Inc Business Overview
  46. 6.8.3 Amgen, Inc Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Amgen, Inc Immuno-oncology Drugs Product Portfolio
  48. 6.8.5 Amgen, Inc Recent Developments
  49. 6.9 AbbVie, Inc.
  50. 6.9.1 AbbVie, Inc. Company Information
  51. 6.9.2 AbbVie, Inc. Business Overview
  52. 6.9.3 AbbVie, Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 AbbVie, Inc. Immuno-oncology Drugs Product Portfolio
  54. 6.9.5 AbbVie, Inc. Recent Developments
  55. 6.10 AstraZeneca, Plc
  56. 6.10.1 AstraZeneca, Plc Company Information
  57. 6.10.2 AstraZeneca, Plc Business Overview
  58. 6.10.3 AstraZeneca, Plc Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio
  60. 6.10.5 AstraZeneca, Plc Recent Developments
  61. 6.11 Spring Bank Pharmaceuticals, Inc.
  62. 6.11.1 Spring Bank Pharmaceuticals, Inc. Company Information
  63. 6.11.2 Spring Bank Pharmaceuticals, Inc. Business Overview
  64. 6.11.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio
  66. 6.11.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
  67. 6.12 Prometheus Therapeutics & Diagnostics
  68. 6.12.1 Prometheus Therapeutics & Diagnostics Company Information
  69. 6.12.2 Prometheus Therapeutics & Diagnostics Business Overview
  70. 6.12.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio
  72. 6.12.5 Prometheus Therapeutics & Diagnostics Recent Developments
  73. 6.13 Novartis International AG
  74. 6.13.1 Novartis International AG Company Information
  75. 6.13.2 Novartis International AG Business Overview
  76. 6.13.3 Novartis International AG Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Novartis International AG Immuno-oncology Drugs Product Portfolio
  78. 6.13.5 Novartis International AG Recent Developments
  79. 6.14 Incyte
  80. 6.14.1 Incyte Company Information
  81. 6.14.2 Incyte Business Overview
  82. 6.14.3 Incyte Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Incyte Immuno-oncology Drugs Product Portfolio
  84. 6.14.5 Incyte Recent Developments
  85. 6.15 ImmunoCellular Therapeutics
  86. 6.15.1 ImmunoCellular Therapeutics Company Information
  87. 6.15.2 ImmunoCellular Therapeutics Business Overview
  88. 6.15.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio
  90. 6.15.5 ImmunoCellular Therapeutics Recent Developments
  91. 6.16 Hoffmann-La Roche AG
  92. 6.16.1 Hoffmann-La Roche AG Company Information
  93. 6.16.2 Hoffmann-La Roche AG Business Overview
  94. 6.16.3 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio
  96. 6.16.5 Hoffmann-La Roche AG Recent Developments
  97. 6.17 Gilead Sciences Inc.
  98. 6.17.1 Gilead Sciences Inc. Company Information
  99. 6.17.2 Gilead Sciences Inc. Business Overview
  100. 6.17.3 Gilead Sciences Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio
  102. 6.17.5 Gilead Sciences Inc. Recent Developments
  103. 6.18 Galena Biopharma
  104. 6.18.1 Galena Biopharma Company Information
  105. 6.18.2 Galena Biopharma Business Overview
  106. 6.18.3 Galena Biopharma Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio
  108. 6.18.5 Galena Biopharma Recent Developments
  109. 6.19 Enzo Biochem, Inc.
  110. 6.19.1 Enzo Biochem, Inc. Company Information
  111. 6.19.2 Enzo Biochem, Inc. Business Overview
  112. 6.19.3 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio
  114. 6.19.5 Enzo Biochem, Inc. Recent Developments
  115. 6.20 EMD Serono, Inc.
  116. 6.20.1 EMD Serono, Inc. Company Information
  117. 6.20.2 EMD Serono, Inc. Business Overview
  118. 6.20.3 EMD Serono, Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio
  120. 6.20.5 EMD Serono, Inc. Recent Developments
  121. 6.21 Dendreon Corporation
  122. 6.21.1 Dendreon Corporation Company Information
  123. 6.21.2 Dendreon Corporation Business Overview
  124. 6.21.3 Dendreon Corporation Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  125. 6.21.4 Dendreon Corporation Immuno-oncology Drugs Product Portfolio
  126. 6.21.5 Dendreon Corporation Recent Developments
  127. 6.22 Celldex Therapeutics
  128. 6.22.1 Celldex Therapeutics Company Information
  129. 6.22.2 Celldex Therapeutics Business Overview
  130. 6.22.3 Celldex Therapeutics Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  131. 6.22.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio
  132. 6.22.5 Celldex Therapeutics Recent Developments
  133. 6.23 Celgene Corporation
  134. 6.23.1 Celgene Corporation Company Information
  135. 6.23.2 Celgene Corporation Business Overview
  136. 6.23.3 Celgene Corporation Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  137. 6.23.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio
  138. 6.23.5 Celgene Corporation Recent Developments
  139. 6.24 Bristol-Myers Squibb
  140. 6.24.1 Bristol-Myers Squibb Company Information
  141. 6.24.2 Bristol-Myers Squibb Business Overview
  142. 6.24.3 Bristol-Myers Squibb Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  143. 6.24.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio
  144. 6.24.5 Bristol-Myers Squibb Recent Developments
  145. 6.25 Bio-Rad Laboratories, Inc.
  146. 6.25.1 Bio-Rad Laboratories, Inc. Company Information
  147. 6.25.2 Bio-Rad Laboratories, Inc. Business Overview
  148. 6.25.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  149. 6.25.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio
  150. 6.25.5 Bio-Rad Laboratories, Inc. Recent Developments
  151. 6.26 Bavarian Nordic
  152. 6.26.1 Bavarian Nordic Company Information
  153. 6.26.2 Bavarian Nordic Business Overview
  154. 6.26.3 Bavarian Nordic Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  155. 6.26.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio
  156. 6.26.5 Bavarian Nordic Recent Developments
  157. 6.27 Avantor, Inc.
  158. 6.27.1 Avantor, Inc. Company Information
  159. 6.27.2 Avantor, Inc. Business Overview
  160. 6.27.3 Avantor, Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  161. 6.27.4 Avantor, Inc. Immuno-oncology Drugs Product Portfolio
  162. 6.27.5 Avantor, Inc. Recent Developments
  163. 6.28 Agilent Technologies Inc.
  164. 6.28.1 Agilent Technologies Inc. Company Information
  165. 6.28.2 Agilent Technologies Inc. Business Overview
  166. 6.28.3 Agilent Technologies Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  167. 6.28.4 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio
  168. 6.28.5 Agilent Technologies Inc. Recent Developments
  169. 6.29 Agenus Inc.
  170. 6.29.1 Agenus Inc. Company Information
  171. 6.29.2 Agenus Inc. Business Overview
  172. 6.29.3 Agenus Inc. Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  173. 6.29.4 Agenus Inc. Immuno-oncology Drugs Product Portfolio
  174. 6.29.5 Agenus Inc. Recent Developments
  175. 6.30 Aduro BioTech
  176. 6.30.1 Aduro BioTech Company Information
  177. 6.30.2 Aduro BioTech Business Overview
  178. 6.30.3 Aduro BioTech Immuno-oncology Drugs Revenue, Global Share and Gross Margin (2021-2026)
  179. 6.30.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio
  180. 6.30.5 Aduro BioTech Recent Developments
7 North America
  1. 7.1 North America Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Immuno-oncology Drugs Market Size by Country (2021-2026)
  3. 7.3 North America Immuno-oncology Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Immuno-oncology Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe Immuno-oncology Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Immuno-oncology Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Immuno-oncology Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Immuno-oncology Drugs Market Size by Country (2021-2026)
  3. 10.3 South America Immuno-oncology Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Immuno-oncology Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst